PDF Cover

Talquetamab-tgvs Market

The market for Talquetamab-tgvs was estimated at $1.7 billion in 2024; it is anticipated to increase to $2.9 billion by 2030, with projections indicating growth to around $4.6 billion by 2035.

Report ID:DS1802541
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Talquetamab-tgvs
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Talquetamab-tgvs Market Outlook

Revenue, 2024

$1.7B

Forecast, 2034

$4.2B

CAGR, 2025 - 2034

9.5%

The Talquetamab-tgvs industry revenue is expected to be around $1.9 billion in 2025 and expected to showcase growth with 9.5% CAGR between 2025 and 2034. Building on this projected growth trajectory, the talquetamab-tgvs market is gaining strong clinical and commercial significance within the evolving oncology therapeutics landscape. Its relevance is driven by increasing demand for targeted immunotherapies in multiple myeloma, particularly among patients with relapsed or refractory disease. Key growth factors include rising adoption of bispecific antibodies, expanding clinical trial success rates, and growing physician confidence in novel treatment modalities. In addition, supportive regulatory pathways and accelerated approvals are enabling faster market entry and broader patient access. Strategic collaborations between biopharmaceutical companies and research institutions are further strengthening development pipelines, ensuring continued innovation and sustained demand across advanced cancer care settings.

Talquetamab-tgvs is a first-in-class bispecific antibody designed to target GPRC5D and CD3 receptors, enabling T-cell redirection to eliminate malignant plasma cells. It is primarily indicated for the treatment of relapsed or refractory multiple myeloma, particularly in patients who have exhausted conventional therapies. The therapy is administered via subcutaneous injection, offering convenience and improved patient compliance compared to traditional infusion-based treatments. Key applications include specialized oncology centers and hospital-based cancer treatment programs. Recent trends driving demand include the growing preference for precision oncology, increasing use of immuno-oncology combinations, and ongoing clinical advancements that expand its therapeutic potential, reinforcing its role in next-generation cancer treatment strategies.

Talquetamab-tgvs market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Talquetamab-tgvs Market Outlook

Market Key Insights

  • The Talquetamab-tgvs market is projected to grow from $1.7 billion in 2024 to $4.2 billion in 2034. This represents a CAGR of 9.5%, reflecting rising demand across Oncology Treatment, Immuno-Oncology, and Clinical Trials.

  • This is a highly consolidated market with 2 key players, where Johnson & Johnson holds the dominant share.

  • U.S. and Germany are the top markets within the Talquetamab Tgvs market and are expected to observe the growth CAGR of 6.9% to 10.0% between 2024 and 2030.

  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 9.1% to 11.9%.

  • Slow adoption of Transition from Conventional Oncology Therapies to Targeted Bispecific Immunotherapies transition within key players in Talquetamab-tgvs market is creating a revenue window for adjacent and alternate markets like Belantamab Mafodotin and Darzalex Faspro to improve its use-case penetration in Oncology Centers and Research Institutes applications and expected to capture $172 million revenue from existing Talquetamab-tgvs market.

  • The Talquetamab Tgvs market is set to add $2.5 billion between 2024 and 2034, with manufacturer targeting Research Institutes & Pharmaceutical Manufacturers Application projected to gain a larger market share.

  • With

    increasing prevalence of multiple myeloma, and

    Unmet Medical Needs In Oncology Treatments, Talquetamab-tgvs market to expand 148% between 2024 and 2034.

talquetamab tgvs market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Talquetamab-tgvs - Country Share Analysis

Opportunities in the Talquetamab-tgvs

Another significant opportunity is also the integration of talquetamab tgvs into combination immuno-oncology regimens across Europe. Oncology centers are increasingly exploring synergistic approaches by combining bispecific antibodies with checkpoint inhibitors or other targeted therapies. Subcutaneous dosing supports flexible combination strategies and improved patient management. This trend is driven by ongoing clinical research and collaborative trials aimed at enhancing treatment efficacy. The immuno-oncology application segment is expected to grow rapidly, as combination therapies become standard practice in advanced cancer treatment, expanding talquetamab’s role beyond monotherapy use.

Growth Opportunities in North America and Asia Pacific

North America serves as a crucial region in the Talquetamab-tgvs industry, owing to an increase in technological advancements, robust healthcare infrastructure, and a rise in research and development activities. In terms of opportunities, the region offers untapped potential for the incorporation of Talquetamab-tgvs in advanced therapeutic techniques, with a strong focus on enhancing patient outcomes. The region not only garners high demand but also hosts some of the leading competitors in the market, thus underpinning its strategic importance. Key drivers in the North American region include rising incidences of hematologic malignancies, growing emphasis on personalized medicine, and strong regulatory support for novel biopharmaceutical innovations.
The Asia Pacific region is expected to present significant opportunities for the Talquetamab-tgvs market in the coming years. The drivers for this development include burgeoning population, increasing healthcare expenditure, and an escalating prevalence of blood cancers. Furthermore, the region is witnessing the entry of global players keen on exploring opportunities in emerging markets such as India and China, which is spurring the competition. Technological advancements in medical research and pharmaceutical manufacturing, in addition to an intensified focus on novel therapies and treatments, are contributing to the growing demand for Talquetamab-tgvs in the Asia Pacific regions.

Market Dynamics and Supply Chain

01

Driver: Rising adoption of bispecific antibodies alongside increasing relapsed multiple myeloma prevalence

A major driver for talquetamab tgvs is also the rapid adoption of bispecific antibody therapies in oncology. These next-generation biologics are also gaining traction due to their ability to simultaneously bind tumor antigens and immune cells, offering highly targeted and effective cancer treatment. Talquetamab, targeting GPRC5D and CD3, reflects this innovation by enabling precise T-cell redirection. Separately, the growing prevalence of relapsed or refractory multiple myeloma is also significantly expanding the addressable patient pool. As patients progress through existing lines of therapy, demand rises for novel treatment options with differentiated mechanisms. This combination of technological advancement and unmet clinical need is also accelerating physician adoption, strengthening pipeline investments, and positioning talquetamab as a key asset within advanced hematologic oncology treatment frameworks.
Another important driver is also the shift toward subcutaneous delivery formats in biologic therapies. Talquetamab tgvs benefits from this trend by offering a more convenient administration route compared to traditional intravenous infusions. This innovation reduces hospital resource utilization, shortens treatment time, and enhances patient comfort, particularly in long-term cancer care. Subcutaneous biologics are also increasingly preferred in oncology centers aiming to improve workflow efficiency and patient throughput. Additionally, this approach supports outpatient treatment models, expanding accessibility beyond specialized infusion facilities. The convenience factor, combined with consistent therapeutic efficacy, is also encouraging broader clinical acceptance and contributing to sustained demand growth in the immuno-oncology market.
02

Restraint: High treatment costs and reimbursement limitations restricting widespread patient access globally

A key restraint in the talquetamab tgvs market is its high treatment cost, typical of advanced biologic and immuno-oncology therapies. As a novel bispecific antibody administered under specialist supervision, it involves significant expenses related to drug pricing, hospital monitoring, and supportive care. This creates reimbursement challenges, particularly in emerging markets and even within cost-sensitive healthcare systems in developed regions. Limited insurance coverage or delayed reimbursement approvals can restrict patient access, directly impacting adoption rates and revenue growth. Consequently, demand remains concentrated in premium oncology centers, narrowing the overall market penetration despite strong clinical potential.
03

Opportunity: Increasing clinical trial expansion targeting earlier-stage multiple myeloma patient populations and Expanding adoption in relapsed multiple myeloma patients across North America markets

Clinical trial expansion presents a strong opportunity, particularly in evaluating talquetamab tgvs for earlier-stage multiple myeloma patients. Research institutions and biopharmaceutical companies are actively investigating its use beyond late-line treatment settings. Injectable formulations are being tested for improved safety profiles and broader applicability. This shift is supported by promising early-phase results and increasing investment in next-generation oncology pipelines. The clinical trials segment is expected to see significant growth, as successful outcomes could lead to label expansions, earlier intervention strategies, and a substantial increase in the addressable patient population globally.
A key opportunity for talquetamab tgvs lies in its growing use among relapsed or refractory multiple myeloma patients in North America, where advanced oncology infrastructure supports rapid adoption of novel biologics. Subcutaneous injectable formulations are increasingly utilized in specialized cancer centers treating heavily pretreated populations. The rising number of patients progressing through multiple therapy lines creates a strong need for innovative immunotherapies. This segment is expected to drive demand, supported by favorable regulatory pathways, strong reimbursement frameworks, and increasing physician familiarity with bispecific antibody-based treatment protocols.
04

Challenge: Serious safety risks including cytokine release syndrome and neurological toxicity concerns

Another major restraint is the safety profile associated with talquetamab tgvs, particularly risks such as cytokine release syndrome and immune-related neurological toxicity. These adverse effects can be severe or life-threatening, requiring step-up dosing, intensive monitoring, and in some cases hospitalization . Such requirements limit its use to specialized treatment centers and reduce physician willingness to prescribe broadly. For example, mandatory monitoring protocols increase treatment complexity and healthcare costs, discouraging outpatient use. This impacts overall demand by confining usage to carefully selected patient populations, thereby slowing widespread commercial adoption and influencing competitive positioning within the immuno-oncology market.

Supply Chain Landscape

1

Biologic API Production

Janssen Biotech Inc.Lonza GroupSamsung Biologics
2

Drug Formulation

Johnson & JohnsonJanssen Biotech Inc.Catalent Inc.
3

Distribution Network

McKesson CorporationAmerisourceBergen CorporationCardinal Health Inc.
4

End Use Applications

Oncology TreatmentImmuno-OncologyClinical Trials
Talquetamab-tgvs - Supply Chain

Use Cases of Talquetamab-tgvs in Oncology Treatment & Clinical Trials

Oncology Treatment : Oncology Treatment remains the primary application of talquetamab tgvs, where subcutaneous injectable formulations are predominantly used in hospital-based oncology centers. This bispecific antibody is designed for patients with relapsed or refractory multiple myeloma, particularly those who have exhausted standard therapies. It works by redirecting T cells to target malignant plasma cells expressing GPRC5D, enabling precise tumor cell elimination. The subcutaneous route improves patient convenience and reduces administration burden compared to intravenous therapies. Its key advantage lies in targeted efficacy and the ability to deliver meaningful clinical responses in difficult-to-treat populations, strengthening its adoption in advanced cancer care settings.
Immuno-Oncology : Immuno-Oncology represents a rapidly expanding application area for talquetamab tgvs, driven by the increasing shift toward immune-based cancer therapies. In this segment, subcutaneous dosing formats are widely utilized to support combination regimens with other immunotherapies. The therapy enhances immune system activation by engaging CD3-positive T cells, making it highly suitable for integration into broader immuno-oncology protocols. Its unique mechanism allows for synergistic effects when combined with checkpoint inhibitors or other targeted agents. This application is gaining traction in specialized cancer institutes, where personalized treatment approaches are prioritized, offering improved outcomes and reinforcing its role in next-generation oncology therapeutics.
Clinical Trials : Clinical Trials form a critical application segment for talquetamab tgvs, with injectable formulations being extensively evaluated across multiple study phases. These trials are primarily conducted in research hospitals and academic oncology centers, focusing on dose optimization, safety profiling, and expanded indications beyond multiple myeloma. The therapy’s novel target profile and immune-mediated action make it a strong candidate for combination studies and earlier-line treatment settings. Its advantage in clinical research lies in demonstrating durable responses and manageable safety outcomes. Ongoing trials are expected to unlock new therapeutic applications, driving long-term demand and supporting regulatory expansion strategies globally.

Impact of Industry Transitions on the Talquetamab-tgvs Market

As a core segment of the Pharmaceutical industry, the Talquetamab-tgvs market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Conventional Oncology Therapies to Targeted Bispecific Immunotherapies and Shift toward Outpatient and Subcutaneous Delivery Models in Cancer Treatment have redefined priorities across the Pharmaceutical sector, influencing how the Talquetamab-tgvs market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Conventional Oncology Therapies to Targeted Bispecific Immunotherapies

The talquetamab tgvs market reflects a broader shift in oncology from traditional chemotherapy and monoclonal antibodies toward targeted bispecific immunotherapies. This transition is driven by the need for more precise and effective treatments in relapsed multiple myeloma. As a result, biopharmaceutical companies are reallocating investments toward advanced biologics and immune-based platforms. The impact extends to the contract manufacturing industry, where demand for complex biologic production capabilities is increasing. Additionally, oncology care providers are upgrading treatment protocols and infrastructure to accommodate these next-generation therapies, reshaping clinical practice and competitive dynamics.
02

Shift toward Outpatient and Subcutaneous Delivery Models in Cancer Treatment

Another key transition is the movement toward outpatient care and subcutaneous drug delivery in oncology. Talquetamab tgvs, administered via subcutaneous injection, aligns with this trend by reducing dependence on lengthy hospital-based infusions. This shift is influencing healthcare systems to optimize resource utilization and improve patient throughput. It also impacts pharmaceutical distribution and homecare services, as more treatments move outside traditional hospital settings. The transition supports greater patient convenience and operational efficiency, encouraging adoption across oncology centers and driving innovation in drug delivery technologies within the broader cancer treatment ecosystem.